Operating Cash Flow CAGR: +40.01% (5Y, annualized)

Over longer horizons, Operating Cash Flow CAGR averages 38.82% over 3 years and 40.01% over 5 years; the trailing 12 months came in at +49.44%.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Halozyme Therapeutics, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.